Amgen Inc. $AMGN Position Raised by Csenge Advisory Group

Csenge Advisory Group boosted its position in Amgen Inc. (NASDAQ:AMGN) by 32.1% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 8,429 shares of the medical research company’s stock after purchasing an additional 2,046 shares during the period. Csenge Advisory Group’s holdings in Amgen were worth $2,379,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Legacy Investment Solutions LLC acquired a new stake in shares of Amgen in the second quarter valued at $27,000. Evelyn Partners Investment Management LLP bought a new stake in Amgen in the second quarter worth about $32,000. Howard Hughes Medical Institute acquired a new stake in Amgen in the 2nd quarter valued at about $32,000. Quaker Wealth Management LLC boosted its position in shares of Amgen by 200.0% during the 2nd quarter. Quaker Wealth Management LLC now owns 120 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 240 shares in the last quarter. Finally, Nvwm LLC grew its stake in shares of Amgen by 893.3% in the 2nd quarter. Nvwm LLC now owns 149 shares of the medical research company’s stock worth $42,000 after purchasing an additional 134 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, SVP Rachna Khosla sold 890 shares of the company’s stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $336.24, for a total value of $299,253.60. Following the transaction, the senior vice president directly owned 7,082 shares of the company’s stock, valued at approximately $2,381,251.68. This represents a 11.16% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Nancy A. Grygiel sold 3,139 shares of the stock in a transaction on Thursday, November 20th. The stock was sold at an average price of $337.26, for a total value of $1,058,659.14. Following the sale, the senior vice president owned 7,225 shares of the company’s stock, valued at approximately $2,436,703.50. This represents a 30.29% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 10,908 shares of company stock worth $3,674,966 in the last ninety days. Corporate insiders own 0.76% of the company’s stock.

Analyst Upgrades and Downgrades

AMGN has been the subject of a number of research reports. Deutsche Bank Aktiengesellschaft raised their target price on shares of Amgen from $280.00 to $285.00 and gave the stock a “hold” rating in a report on Tuesday, November 11th. Daiwa Capital Markets raised their price objective on Amgen from $310.00 to $370.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 18th. The Goldman Sachs Group lifted their target price on Amgen from $400.00 to $403.00 and gave the stock a “buy” rating in a report on Thursday, January 8th. Argus upped their target price on Amgen from $310.00 to $360.00 and gave the company a “buy” rating in a report on Tuesday, December 30th. Finally, Wells Fargo & Company increased their price target on Amgen from $300.00 to $325.00 and gave the company an “equal weight” rating in a research report on Wednesday, December 10th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $339.45.

Amgen Stock Up 0.1%

Shares of Amgen stock opened at $330.41 on Friday. The company has a current ratio of 1.28, a quick ratio of 0.99 and a debt-to-equity ratio of 5.45. Amgen Inc. has a 1 year low of $261.43 and a 1 year high of $346.38. The stock has a 50-day moving average price of $331.56 and a 200 day moving average price of $306.12. The company has a market cap of $177.92 billion, a P/E ratio of 25.53, a P/E/G ratio of 2.94 and a beta of 0.45.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, November 4th. The medical research company reported $5.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.01 by $0.63. The business had revenue of $9.56 billion during the quarter, compared to analyst estimates of $8.98 billion. Amgen had a net margin of 19.47% and a return on equity of 162.59%. The firm’s revenue was up 12.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $5.58 earnings per share. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. As a group, analysts expect that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 13th will be issued a dividend of $2.52 per share. The ex-dividend date is Friday, February 13th. This represents a $10.08 annualized dividend and a dividend yield of 3.1%. This is an increase from Amgen’s previous quarterly dividend of $2.38. Amgen’s dividend payout ratio is presently 77.90%.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.